cerrar
Tagged with USA,

Gary Zieziula – President & Region Head North America,…
Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the…

US Elections: Biden & Trump’s Unworkable Drug Pricing…
In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on…

Peter Marks – Director, Center for Biologics Evaluation and…
Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights…

This Could Get Messy: Trump’s New ‘Most Favoured Nation’…
Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive…

Biosimilar Adoption in the US: Still Lagging Behind Europe
As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

US Biotech Commercialisation Strategies: How Karyopharm &…
With US still the reigning global champion in biotech innovation, the dynamic and vibrant biopharma ecosystem in the world’s largest healthcare…

Supporting Value-Based Purchasing in the US Through Changes in…
Michael Ciarametaro, VP for Research at the US National Pharmaceutical Council (NPC), outlines issues surrounding the outdated Medicaid Best Price…

Japanese Pharma’s Skyrocketing US Footprint
Following PharmaBoardroom’s recent interview with Ivan Cheung, chairman of Eisai’s US affiliate and president of Eisai’s global neurology…

Michael G. Kauffman – Founder & CEO, Karyopharm…
Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product…

Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…

J&J’s Momenta Deal A Further Sign of Big Pharma’s Rare…
In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition…

Lundbeck US Head on COVID-19’s Dramatic Mental Health Impact
PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here